| 2017-08-08 16:59:51|
MYGN 16:59 08/08 08/08/17
Myriad Genetics reports Q4 adjusted EPS 30c, consensus 26c
Reports Q4 revenue $200.5M, consensus $193.74M. The company said, "This quarter we saw record demand for hereditary cancer tests and now have 86 percent of our hereditary cancer revenue under long-term contract, providing future stability upon which to build our growing portfolio of new products. Our diversification efforts showed continued success with new products representing greater than two-thirds of test volume and 28 percent of revenue in the fourth-quarter. Our strong progress on transforming the company leaves us well positioned to achieve our long-term strategic goals."